News Sentiment

GHRS sentiment intelligence

GH Research PLC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 28.71 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

75/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+8.3% over one week, +29.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Price-Driven Insight from (GHRS) for Rule-Based Strategy

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 75/100 classification
One-week reaction 8.3% Price confirming higher
Trend fit Trend active 29.1% over four weeks
Fair value 136.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 33
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
TradingView 9
Investing.com 4
Stock Traders Daily 3
TradingKey 3
GlobeNewswire 3
Benzinga 2
Sahm 2

Event Lens

What the news is about

Classified themes
Earnings 23
Market update 17
Analyst action 4
Guidance 3
Deals and strategy 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-50 of 50
Simply Wall Street Direct company coverage

Do GH Research’s (GHRS) Phase 2a Postpartum Data Subtly Reframe Its Broader Depression Strategy?

GH Research (GHRS) recently published positive Phase 2a results for inhaled Mebufotenin (GH001) in postpartum depression, showing rapid remission and good tolerability. While these results strengthen the medical case for GH001 across depressive disorders, the market remains conce

Tone
Neutral 50/100
Event
Earnings
Published
11 Jun 2026 04:39
Source
Simply Wall Street